Effect of Sodium Valproate on the Toxicity of Cyclophosphamide in the Testes of Mice: Influence of Pre"‘ and Post"‘Treatment Schedule

Jump To References Section

Authors

  • S. Khan
     ,IN
  • G. B. Jena
     ,IN

Keywords:

Cyclophosphamide, DNA damage, histone deacetylase inhibitor, mice, sodium valproate

Abstract

Recently, sodium valproate (VPA) has been proven as histone deacetylase (HDAC) inhibitor and potentiates the cytotoxicity of anticancer drugs, and also exhibit promising anti"‘cancer activity. Present study aimed to investigate the influence of pre"‘ and post"‘treatment of VPA on cyclophosphamide (CP) induced genotoxicity and germ cell toxicity in mice. All the animals were treated with VPA at the dose of 500 mg/kg/day on alternate day thrice/week for a period of two weeks, CP at the dose of 200 mg/kg on 7th and 15th day and sacrificed 24 h after administration (i.p.) of the last dose. End point of evaluation includes sperm count, sperm head morphology, sperm comet assay and histology. VPA treatment significantly decreases CP induced sperm count, testes and epididymis weight; increased sperm head abnormality and sperm DNA damage. Both VPA pre"‘ and post"‘treatment augmented CP induced DNA damage and the germ cell toxicity; however, pre"‘treatment induced more cytotoxicity and genotoxicity as compared to post"‘treatment.

Downloads

Download data is not yet available.

Downloads

Published

2018-08-09

How to Cite

Khan, S., & Jena, G. B. (2018). Effect of Sodium Valproate on the Toxicity of Cyclophosphamide in the Testes of Mice: Influence of Pre"‘ and Post"‘Treatment Schedule. Toxicology International, 20(1), 68–76. Retrieved from https://informaticsjournals.co.in/index.php/toxi/article/view/21711

Issue

Volume 20, Issue 1, January - April 2013

Section

Original Research
Received 2018-08-09
Accepted 2018-08-09
Published 2018-08-09

 

References

Arce C, Pérez"‘Plasencia C, González"‘Fierro A, de la Cruz"‘ Hernández E, Revilla"‘Vázquez A, Chávez"‘Blanco A, et al.A proof"‘of"‘principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 2006;1:e98.

Duenas"‘Gonzalez A, Candelaria M, Perez"‘Plascencia C, Perez"‘Cardenas E, de la Cruz"‘Hernandez E, Herrera LA.Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008;34:206"‘22.

Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008;269:7"‘17.

Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, et al. A phase I"‘II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009;100:28"‘36.

LeBaron MJ, Rasoulpour RJ, Klapacz J, Ellis"‘Hutchings RG, Hollnagel HM, Gollapudi BB. Epigenetics and chemical safety assessment. Mutat Res 2010;705:83"‘95.

Moggs JG, Goodman JI, Trosko JE, Roberts RA. Epigenetics and cancer: Implications for drug discovery and safety assessment.Toxicol Appl Pharmacol 2004;196:422"‘30.

Tripathi DN, Jena GB. Ebselen attenuates cyclophosphamideinduced oxidative stress and DNA damage in mice. Free Radic Res 2008;42:966"‘77.

Ahmed AR, Hombal SM. Cyclophosphamide (Cytoxan): A review on relevant pharmacology and clinical uses. J Am Acad Dermatol 1984;11:1115"‘26.

Atmaca A, Al"‘Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, et al. Valproic acid (VPA) in patients with refractory advanced cancer: A dose escalating phase I clinical trial. Br J Cancer 2007;97:177"‘82.

Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010;2010:1"‘18.

Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN.In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 2005;4:1993"‘2000.

Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 2005;65:3815"‘22.

Sawan C, Vaissière T, Murr R, Herceg Z. Epigenetic drivers and genetic passengers on the road to cancer. Mutat Res 2008;642:1"‘13.

Kostrouchová M, Kostrouch Z, Kostrouchová M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 2007;53:37"‘49.

Szyf M. The dynamic epigenome and its implications in toxicology. Toxicol Sci 2007;100:7"‘23.

Carrell DT, Hammoud SS. The human sperm epigenome and its potential role in embryonic development. Mol Hum Reprod 2010;16:37"‘47.

Godmann M, Lambrot R, Kimmins S. The dynamic epigenetic program in male germ cells: Its role in spermatogenesis, testis cancer, and its response to the environment. Microsc Res Tech 2009;72:603"‘19.

Tripathi DN, Jena GB. Astaxanthin inhibits cytotoxic and genotoxic effects of cyclophosphamide in mice germ cells.Toxicology 2008;248:96"‘103.

Woo PC, Ng WF, Leung HC, Tsoi HW, Yuen KY. Clarithromycin attenuates cyclophosphamide"‘induced mucositis in mice.Pharmacol Res 2000;41:527"‘32.

Mannaerts I, Nuytten NR, Rogiers V, Vanderkerken K, van Grunsven LA, Geerts A. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology 2010;51:603"‘14.

Burruel VR, Yanagimachi R, Whitten WK. Normal mice develop from oocytes injected with spermatozoa with grossly misshapen heads. Biol Reprod 1996;55:709"‘14.

Wyrobek AJ, Bruce WR. Chemical induction of sperm abnormalities in mice. Proc Natl Acad Sci U S A 1975;72:4425"‘9.

Haines GA, Hendry JH, Daniel CP, Morris ID. Germ cell and dose"‘dependent DNA damage measured by the comet assay in murine spermatozoaa after testicular X"‘irradiation. Biol Reprod 2002;67:854"‘61.

Khan S, Ahmad T, Parekh CV, Trivedi PP, Kushwaha S, Jena G.Investigation on sodium valproate induced germ cell damage, oxidative stress and genotoxicity in male Swiss mice. Reprod Toxicol 2011;32:385"‘94.

Glander HJ, Horn LC, Dorschner W, Paasch U, Kratzsch J.Probability to retrieve testicular spermatozoa in azoospermic patients. Asian J Androl 2000;2:199"‘205.

Almeida FF, Leal MC, França LR. Testis morphometry, duration of spermatogenesis, and spermatogenic efficiency in the wild boar (Sus scrofa scrofa). Biol Reprod 2006;75:792"‘9.

Sun F, Ko E, Martin RH. Is there a relationship between sperm chromosome abnormalities and sperm morphology? Reprod Biol Endocrinol 2006;4:1.

Trivedi PP, Kushwaha S, Tripathi DN, Jena GB. Evaluation of male germ cell toxicity in rats: Correlation between sperm head morphology and sperm comet assay. Mutat Res 2010;703:115"‘21.

Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009;15:2818"‘28.

Hess"‘Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 2005;84:109"‘21.

Barratt CL, Aitken RJ, Björndahl L, Carrell DT, de Boer P, Kvist U, et al. Sperm DNA: Organization, protection and vulnerability: from basic science to clinical applications"‘"‘a position report.Hum Reprod 2010;25:824"‘38.

Trasler JM. Epigenetics in spermatogenesis. Mol Cell Endocrinol 2009;306:33"‘6.